Beclabuvir (BMS-791325)

Beclabuvir (BMS-791325) 是一种变构抑制剂，可与丙型肝炎病毒 (HCV) NS5B RNA 依赖性 RNA 聚合酶的拇指位点 1 结合，并抑制来自 HCV 基因型 1、3、4 和 5 的重组 NS5B 蛋白，IC50 为< 28 海里。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥1512.00

1210.00

- +
5mg

￥3737.00

2990.00

- +
10mg

￥5875.00

4700.00

- +
25mg

￥11762.00

9410.00

- +
50mg

￥16950.00

13560.00

- +
100mg

￥25425.00

20340.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM.

Beclabuvir demonstrates additive or synergistic antiviral activity with pegIFN/RBV and in 2- or 3-drug combinations with a range of DAAs, such as HCV NS3 protease inhibitors, NS5A inhibitors' and/or nucleoside NS5B inhibitors[2].

The combination of beclabuvir with asunaprevir and daclatasvir achieves very high rates of viral eradication (about 90%) in patients infected with HCV genotype 1, which is the most common genotype worldwide[1].

[1]. Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111-21. [2]. Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015 Aug;22(8):658-64.